Do Huntington's Chorea Medications Cause Depression?

Yes, medications used to treat the involuntary twitching (chorea) in Huntington’s disease can cause or worsen depression ^[1][2]. These medications, known as VMAT2 inhibitors, include tetrabenazine, deutetrabenazine, and valbenazine. While they are highly effective at controlling physical movements, they carry a serious risk of neuropsychiatric side effects. In fact, tetrabenazine and deutetrabenazine carry a strict “Black Box” warning from the FDA for depression and suicidal thoughts in patients with Huntington’s disease ^[3][4].

Because Huntington’s disease itself already carries a high baseline risk for depression and suicide, taking these medications requires careful balancing of physical and mental health priorities ^[5].

How Chorea Medications Affect Mood

VMAT2 inhibitors work by decreasing the levels of certain chemical messengers in the brain—particularly dopamine ^[2]. Dopamine helps control movement, so reducing it calms the involuntary twitching (chorea). However, these medications also deplete other mood-regulating chemicals like serotonin and norepinephrine ^[2]. This chemical shift is why patients may experience new or worsening depression, anxiety, or sedation ^[6].

It is also important to distinguish between sedation (excessive sleepiness or physical fatigue) and depression (persistent sadness, hopelessness, or loss of interest). While sedation is a common side effect of starting these medications, persistent feelings of worthlessness, apathy, or emotional numbness are warning signs of depression and should be reported to your doctor immediately.

Are All Medications the Same?

Not all VMAT2 inhibitors carry the exact same level of risk. Newer medications have been designed to process more smoothly in the body, which can mean fewer side effects ^[1][7][8].

Balancing Your Treatment Priorities

Managing Huntington’s disease involves balancing the need to control physical movements with the need to protect mental health. If chorea is interfering with your safety, eating, or daily life, you and your doctor might decide a VMAT2 inhibitor is the right choice ^[10]. To manage the risks safely, your care team will likely take the following steps:

• Pre-treatment screening: Your doctor should thoroughly evaluate your mental health before prescribing a VMAT2 inhibitor ^[2]. If you are experiencing severe, untreated depression or suicidal thoughts, these medications may be delayed or avoided ^[4]. In such cases, your doctor might prescribe alternative medications—such as atypical antipsychotics like olanzapine or aripiprazole—that can help manage chorea without the exact same VMAT2 psychiatric risks.
• Ongoing monitoring: The highest risk for mood crashes typically occurs within the first few days to weeks of starting the medication or increasing the dose ^[2]. You and your caregivers should watch closely for behavioral red flags like sudden apathy, crying spells, or withdrawing from favorite hobbies.
• Adjusting the treatment plan: If depression occurs, your doctor might lower the dose, switch from tetrabenazine to a newer VMAT2 inhibitor, or add an antidepressant to help protect your mood while keeping the chorea under control ^[7][11].

Never stop taking your medication suddenly or change your dose without speaking to your doctor. Always communicate openly about any changes in your mood so your care team can adjust your treatment plan to keep you safe.